FDA director offers QbD insight

Regulators have greater confidence in the quality of drug products developed and manufactured using QbD techniques. And even though the pharma industry is making a great effort to develop processes based on QbD, it needs to update its thinking.

"The area that needs more work is the development of a modern quality strategy that is appropriate for these new technologies, rather than relying on the old checklist approach to control strategies," says Moheb Nasr, director for FDA's Office of New Drug Quality Assessment, in PharmTech.

Another area with room for improvement is aligning existing quality systems with a QbD approach and new technologies, says Nasr. For this task, manufacturers can follow the International Conference on Harmonization's Q10 quality system guidance.

- see the interview


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.